CLBS Insider Trading (Caladrius Biosciences)
Insider Ownership Percentage: 10.30%
Insider Buying (Last 12 Months): $99,945.00
Insider Selling (Last 12 Months): $0.00
Caladrius Biosciences Insider Trading History Chart
Caladrius Biosciences Share Price & Price History
As of 06/21/2021 03:43 PM ET
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
Caladrius Biosciences Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/9/2020||Michael H. Davidson||Director||Buy||55,525||$1.80||$99,945.00|| |
SEC Filings (Institutional Ownership Changes) for Caladrius Biosciences (NASDAQ:CLBS)
11.29% of Caladrius Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
Caladrius Biosciences Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/18/2021||Millennium Management LLC||44,405||$86K||0.0%||N/A||0.075%|
|5/14/2021||Dimensional Fund Advisors LP||61,506||$0.12M||0.0%||+199.3%||0.103%|
|5/13/2021||Renaissance Technologies LLC||1,460,155||$2.82M||0.0%||+39.6%||2.454%|
|5/12/2021||Northern Trust Corp||85,855||$0.17M||0.0%||+398.3%||0.144%|
|5/12/2021||Geode Capital Management LLC||318,153||$0.61M||0.0%||+583.6%||0.535%|
|4/28/2021||Game Plan Financial Advisors LLC||15,000||$29K||0.0%||N/A||0.025%|
|3/8/2021||Dimensional Fund Advisors LP||20,548||$29K||0.0%||-37.1%||0.062%|
|2/25/2021||Dimensional Fund Advisors LP||20,548||$29K||0.0%||-37.1%||0.062%|
|2/24/2021||Virtu Financial LLC||52,599||$75K||0.0%||N/A||0.160%|
|2/16/2021||Squarepoint Ops LLC||20,637||$30K||0.0%||N/A||0.063%|
|2/10/2021||Renaissance Technologies LLC||1,045,855||$1.50M||0.0%||+12.8%||3.173%|
|11/9/2020||Acadian Asset Management LLC||156,668||$0.28M||0.0%||+119.0%||0.811%|
|5/15/2020||Summit Trail Advisors LLC||17,730||$32K||0.0%||N/A||0.138%|
|2/13/2020||Renaissance Technologies LLC||411,401||$1.03M||0.0%||+5.0%||3.956%|
|8/14/2019||Vanguard Group Inc.||207,973||$0.47M||0.0%||+7.6%||1.999%|
|8/12/2019||Renaissance Technologies LLC||380,336||$0.87M||0.0%||+20.6%||3.663%|
|5/9/2019||Wesbanco Bank Inc.||10,000||$36K||0.0%||N/A||0.096%|
|4/1/2019||Deutsche Bank AG||51,011||$0.18M||0.0%||-11.0%||0.513%|
|12/13/2018||Vanguard Group Inc||202,568||$1.20M||0.0%||+2.9%||2.059%|
|11/13/2018||Renaissance Technologies LLC||280,864||$1.66M||0.0%||+42.9%||2.854%|
|8/13/2018||Renaissance Technologies LLC||196,563||$1.27M||0.0%||+33.7%||2.022%|
|5/11/2018||Dimensional Fund Advisors LP||33,765||$0.20M||0.0%||N/A||0.353%|
|5/10/2018||JPMorgan Chase & Co.||18,771||$0.11M||0.0%||N/A||0.196%|
|2/15/2018||Macquarie Group Ltd.||29,890||$0.11M||0.0%||+321.0%||0.316%|
|5/12/2017||KCG Holdings Inc.||36,291||$0.18M||0.0%||+74.6%||0.000%|
|5/12/2017||Renaissance Technologies LLC||97,552||$0.49M||0.0%||+34.3%||0.000%|
|2/13/2017||Renaissance Technologies LLC||72,652||$0.21M||0.0%||+149.2%||0.000%|
|11/15/2016||Knoll Capital Management LP||55,781||$0.27M||0.5%||N/A||0.000%|
|5/16/2016||Jacobs Levy Equity Management Inc.||165,691||$0.12M||0.0%||N/A||0.281%|
|5/13/2016||Geode Capital Management LLC||293,305||$0.22M||0.0%||0.0%||0.530%|
|5/10/2016||BlackRock Institutional Trust Company N.A.||246,414||$0.19M||0.0%||No Change||0.445%|
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Caladrius Biosciences?
Caladrius Biosciences' top insider investors include:
- Michael H Davidson (Director)
Who are the major institutional investors of Caladrius Biosciences?
Caladrius Biosciences' top institutional shareholders include:
- Renaissance Technologies LLC — 2.45%
- BlackRock Inc. — 1.74%
- Geode Capital Management LLC — 0.53%
- Northern Trust Corp — 0.14%
- Morgan Stanley — 0.12%
- Dimensional Fund Advisors LP — 0.10%
Which major investors are buying Caladrius Biosciences stock?
During the last quarter, CLBS stock was acquired by institutional investors including:
- BlackRock Inc.
- Renaissance Technologies LLC
- Geode Capital Management LLC
- Northern Trust Corp
- Morgan Stanley
- Millennium Management LLC
- Dimensional Fund Advisors LP
- Game Plan Financial Advisors LLC